Dr Bauml speaks with ecancertv at ASCO 2016 to discuss the first findings of KEYNOTE 055, a trial for PD-L1/2 blocking pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Pembrolizumab showed promising anti-tumour activity in earlier KEYSTONE 012 results, which are confirmed in this setting with an overall recovery rate of 18% and a stable disease rate of 18%.
Dr Bauml discusses the impact of these findings for those whom platinum and cetuximab therapy had failed, the wider aspects of checkpoint inhibitory therapy, and next steps for the trial.
ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.